Highlights
- •Until today lipoprotein apheresis (LA) is considered the most effective treatment for patients with high-Lp(a).
- •PCSK9i are often combined with LA to dampen the rebound in lipoprotein concentrations.
- •Chronic LA effect on Lp(a) levels is a significant reduction in pre-LA Lp(a) concentrations compared to native Lp(a) value.
- •The administration of Arilocumab 75 mg after 7 days from LA shows a significant pre-LA reduction in the Lp(a) concentrations respect to those obtained with standard administration .
- •In high-Lp(a) patients treated with chronic LA the deferred addition of alirocumab, resulted in lower LDL-cholesterol and Lp(a) values.
Abstract
Until today lipoprotein apheresis (LA) is considered the most effective treatment
for patients with high-Lp(a) and proprotein convertase subtilisin/kexin type 9 inhibitors
(PCSK9i) are often combined with LA to dampen the rebound in lipoprotein concentrations.
The aim of the present work is to evaluate the effect of dose-adjustment strategy
for alirocumab in a small cohort of high-Lp(a) subjects with ischemic heart disease
and in chronic LA treatment. Chronic LA effect on Lp(a) levels is a significant reduction
in pre-LA Lp(a) concentrations compared to native Lp(a) value (118 [116–119] mg/dl
vs 150 [137–155] mg/dl; p < 0.001). Furthermore, the administration of Arilocumab
75 mg after 7 days from LA shows a significant pre-LA reduction in the Lp(a) concentrations
respect to those obtained with administration immediately after the LA treatment.
In high-Lp(a) patients treated with chronic LA the deferred addition of alirocumab,
resulted in lower LDL-cholesterol and Lp(a) values.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Transfusion and Apheresis ScienceAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- RNA drugs lower lipoprotein(a) and genetically driven cholesterol.Nat Biotechnol. 2022; 40: 983-985
- Lipoprotein apheresis for lipoprotein(a)-associated cardiovascular disease: prospective 5 years of follow-up and apolipoprotein(a).Charact Arterioscler Thromb Vasc Biol. 2016; 36: 2019-2027
- 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.Eur Heart J. 2020; 41: 111-188
- Alirocumab in patients with heterozygous familial hypercholesterolaemia undergoing lipoprotein apheresis: the ODYSSEY ESCAPE trial.Eur Heart J. 2016; 37: 3588-3595
- Alirocumab and cardiovascular outcomes after acute coronary syndrome.N Engl J Med. 2018; 379: 2097-2107
- Actual situation of lipoprotein apheresis in patients with elevated lipoprotein(a) levels.Atheroscler Suppl. 2019; 40: 1-7
- A retrospective analysis of clinical use of alirocumab in lipoprotein apheresis patients.J Clin Lipidol. 2020; 14: 818-824
- Elusive therapeutic effect of PCSK9 inhibitors on lipoprotein(a) levels.Ther Apher Dial. 2019; 23: 385-386
Article info
Publication history
Published online: February 21, 2023
Accepted:
February 20,
2023
Received in revised form:
February 17,
2023
Received:
January 2,
2023
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2023 Elsevier Ltd. All rights reserved.
